Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.
Authors
Pashtoon Murtaza Kasi
University Of Iowa, Iowa City, IA
Pashtoon Murtaza Kasi , Li Ma , Kai Treuner , Jenna Wong , Catherine A. Schnabel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Diagnostics
DOI
10.1200/JCO.2022.40.4_suppl.647
Abstract #
647
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
First Author: Ghassan K. Abou-Alfa
Poster
2017 ASCO Annual Meeting
Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
First Author: Maeve Aine Lowery
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world testing, treatment patterns, and outcomes following liquid biopsy in advanced cholangiocarcinoma.
First Author: Amit Mahipal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer